The NOTCH2 variants had a specific pattern of expression during the different stages of AML with 79 % AML patients expressing the variant NOTCH2-Va, during remission 40 % of AML patients were negative for NOTCH2-Va and during relapse 80 % of AML patients expressed this variant. This evidence concerns the gene NOTCH2 and acute myeloid leukemia.